.
logo csic-iccc

Do physicians correctly calculate thromboembolic risk scores? A comparison of concordance between manual and computer-based calculation of CHADS2 and CHA2 DS2 -VASc scores.

2016, Intern Med J. 2016 Mar 1. doi: 10.1111/imj.13048. [Epub ahead of print]
Esteve-Pastor MA1, Marín F1, Martínez VB2, Rabadán IR3, Fillat ÁC4, Badimon L5, García JM6, Valdés M1, Sánchez MA7; FANTASIIA study investigators
Autores del centro relacionados: Badimon Lina.
Author information

1Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain.
2Hospital Universitario San Juan, Alicante, Spain.
3Hospital La Paz, Madrid, Spain.
4Hospital de Bellvitge, Barcelona, Spain.
5Cardiovascular Research Center, CSIC-ICCC, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, Barcelona.
6Hospital Universitario A Coruña, La Coruña, Spain.
7Hospital Universitario Reina Sofía, Córdoba, Spain.

Abstract

Clinical risk scores, CHADS2 and CHA2 DS2 -VASc scores, are established tools for assessing stroke risk in patients with Atrial Fibrillation (AF). The aim of this study is to assess concordance between manual and computer-based calculation of CHADS2 and CHA2 DS2 -VASc scores, as well as to analyze the patient categories using CHADS2 and the potential improvement on stroke risk stratification with CHA2 DS2 -VASc score.
METHODS:
We linked data from Atrial Fibrillation Spanish registry FANTASIIA. Between June 2013 to March 2014, 1318 consecutive outpatients were recruited. We explore the concordance between manual scoring and computer-based calculation. We also compare the distribution of embolic risk of patients using both CHADS2 and CHA2 DS2 -VASc scores RESULTS: The mean age was 73.8 ± 9.4 years and 758 (57.5%) were male. For CHADS2 score, concordance between manual scoring and computer-based calculation was 92.5% whereas for CHA2 DS2 -VASc score was 96.4%. In CHADS2 score, 6.37% of patients with AF changed indication on antithrombotic therapy (3.49% of patients with no treatment changed to need antithrombotic treatment and 2.88% of patients otherwise). Using CHA2 DS2 -VASc score, only 0.45% of patients with AF needed to change in the recommendation of antithrombotic therapy.
CONCLUSION:
We have found a strong concordance between manual and computer-based score calculation of both CHADS2 and CHA2 DS2 -VASc risk scores with minimal changes in anticoagulation recommendations. The use of CHA2 DS2 -VASc score significantly improves classification of atrial fibrillation patients at low and intermediate risk of stroke into higher grade of thromboembolic score. Moreover, CHA2 DS2 -VASc score could identify 'truly low risk" patients compared to CHADS2 score.
This article is protected by copyright. All rights reserved.

KEYWORDS:
Atrial Fibrillation; CHA2DS2-VASc score; Stroke risk score; antithrombotic treatment; oral anticoagulation
PMID: 26929032 [PubMed - as supplied by publisher]
Share on FacebookShare on TwitterShare on Google+

Buscador de publicaciones

Buscar
pie http://www.mec.es http://www.csic.es http://www.iccc.cat http://www10.gencat.net/dursi

Centro de Investigación Cardiovascular CSIC-ICCC
Hospital de la Santa Creu i Sant Pau, Pavelló del Convent
Sant Antoni Maria Claret, 167 08025 Barcelona España
T: +34 - 93 556 5900 F: +34 - 93 556 5559

Aviso legal | Pólitica de Privacidad